Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Cabtreo clindamycin plus benzoyl peroxide and adapalene acne vulgaris Active
Caduet Amlodipine besylate/ atorvastatin calcium Hypertension/ Dyslipidemia List with clinical criteria and/or conditions Complete
Calquence Acalabrutinib Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) Reimburse with clinical criteria and/or conditions Complete
Calquence Acalabrutinib Chronic Lymphocytic Leukemia (CLL) Reimburse with clinical criteria and/or conditions Complete
Camcevi leuprolide Prostate cancer Pending
Campral Acamprosate calcium Alcohol Abstinence List with clinical criteria and/or conditions Complete
Campral Acamprosate calcium Alcohol Abstinence N/A Complete
Camzyos mavacamten Obstructive hypertrophic cardiomyopathy Reimburse with clinical criteria and/or conditions Complete
Caprelsa Vandetanib Medullary Thyroid Cancer Reimburse with clinical criteria and/or conditions Complete
Carvykti ciltacabtagene autoleucel Relapsed or refractory multiple myeloma Reimburse with clinical criteria and/or conditions Complete